Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.35 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.33 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7418633 | 0.98 | GNAO1 (0.39) | GNAO1HRH3ITGB3ITGA2BAVPR2 | |
| SCHEMBL21667847 | 0.91 | SLC6A1 (0.35) | GNAO1HRH3ITGB3ITGA2BAVPR2 | |
| SCHEMBL21667842 | 0.91 | SLC6A1 (0.35) | GNAO1HRH3ITGB3ITGA2BAVPR2 | |
| SCHEMBL21941042 | 0.91 | SLC6A1 (0.35) | GNAO1HRH3ITGB3ITGA2BAVPR2 | |
| SCHEMBL7419450 | 0.88 | GNAO1 (0.35) | GNAO1HRH3ITGB3ITGA2BAVPR2 | |
| SCHEMBL13963782 | 0.85 | CYP1A2 (0.36) | — | |
| SCHEMBL13963779 | 0.81 | CYP1A2 (0.43) | HRH3 | |
| SCHEMBL19700565 | 0.81 | CYP1A2 (0.48) | HRH3 | |
| SCHEMBL7426671 | 0.80 | HRH3 (0.41) | HRH3 | |
| SCHEMBL1308005 | 0.79 | GNAO1 (0.39) | GNAO1HRH3ITGB3ITGA2BAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277434-A1 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | CAI SHAOPEI (US) | 2012-11-01 | — | — | US | disclosed |
| US-8299081-B2 | Methods for treating drug resistant cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8222413-B2 | Methods for synthesizing heterocyclic compounds | NOVARTIS AG (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110046376-A1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS. | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-7598268-B2 | Quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598268-B2 | Quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090215793-A1 | Methods for treating drug resistant cancer | NOVARTIS AG | 2009-08-27 | — | — | US | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7368459-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368459-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070032528-A1 | Heterocyclic compounds | RENHOWE PAUL A | 2007-02-08 | — | — | US | disclosed |
| US-20070032528-A1 | Heterocyclic compounds | RENHOWE PAUL A | 2007-02-08 | — | — | US | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | GNAO1 807/4885HRH3 1863/4885ITGB3 4020/4885 |
| US-20070032528-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | GNAO1 441/4885HRH3 881/4885ITGB3 2418/4885 |
| US-20120277434-A1 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | KCNJ2, KCNQ2, KCNJ11 | GNAO1 705/4885HRH3 3024/4885ITGB3 4760/4885 |
| US-20110046376-A1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS. | NISCH, DOHH, DNPH1 | GNAO1 472/4885HRH3 147/4885ITGB3 4823/4885 |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | GNAO1 2796/4885HRH3 1232/4885ITGB3 4254/4885 |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | GNAO1 807/4885HRH3 1863/4885ITGB3 4020/4885 |
| US-20090215793-A1 | Methods for treating drug resistant cancer | ABCC1, SLC11A2, SLC10A1 | GNAO1 1882/4885HRH3 3970/4885ITGB3 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.